PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia.
Source check: Needs source check. Not independent scientific confirmation.
Finding / tested result: Generated candidates underwent further filtering and selection; biochemical measurements support differential mutant/wild-type inhibition. This is preclinical enzyme evidence.
Technology: LSTM recurrent generative neural network
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- LSTM recurrent generative neural network is the AI method documented in the editorial source review.
- Limitation / still unknown
- The date refers to the cited version. Earlier public versions and independent replication were not systematically verified.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.3389/fmolb.2022.1072028
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.